{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:16:25Z","timestamp":1788992185383,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["18E2H24N"],"award-info":[{"award-number":["18E2H24N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Early Human Development"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.earlhumdev.2024.106136","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:02:03Z","timestamp":1730286123000},"page":"106136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Advocating for drug development in newborn infants"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-5105","authenticated-orcid":false,"given":"Karel","family":"Allegaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-7264","authenticated-orcid":false,"given":"Souvik","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-6698","authenticated-orcid":false,"given":"Anne","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-8656","authenticated-orcid":false,"given":"Mark A.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.earlhumdev.2024.106136_bb0005","unstructured":"AAP News, Historic milestone: 1,000 drugs, biologics have new pediatric use information in labeling. Available from: https:\/\/www.fda.gov\/media\/161414\/download?attachment, 2022."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/cpt.166","article-title":"Neonatal drug therapy: the first frontier of therapeutics for children","volume":"98","author":"Allegaert","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0015","doi-asserted-by":"crossref","unstructured":"N.M. Lai, S.K. Veettil, N. Chaiyakunapruk, P. Glasziou, Are newer drugs better? An analysis of neonatal pharmacological treatments across generations, Med. Princ. Pract. June 10, doi: https:\/\/doi.org\/10.1159\/000539729.","DOI":"10.1159\/000539729"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0020","unstructured":"U.S. Food and Drug Administration, Clinical outcome assessment (COA): frequently asked questions. Available from: https:\/\/www.fda.gov\/about-fda\/clinical-outcome-assessment-coa-frequently-asked-questions, 2020."},{"issue":"7","key":"10.1016\/j.earlhumdev.2024.106136_bb0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/pharmaceutics12070685","article-title":"Approaches to dose finding in neonates, illustrating the variability between neonatal drug development programs","volume":"12","author":"Van den Anker","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.earlhumdev.2024.106136_bb0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41372-021-01304-2","article-title":"Challenges and opportunities for improving access to approved neonatal drugs and devices","volume":"42","author":"Lewis","year":"2022","journal-title":"J. Perinatol."},{"issue":"11","key":"10.1016\/j.earlhumdev.2024.106136_bb0035","article-title":"Stem cell-based interventions for the treatment of stroke in newborn infants","volume":"11","author":"Bruschettini","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.earlhumdev.2024.106136_bb0040","article-title":"Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants","volume":"11","author":"Pierro","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/ijns10030049","article-title":"Systematic review of newborn screening programmes for spinal muscular atrophy","volume":"10","author":"Cooper","year":"2024","journal-title":"Int. J. Neonatal Screen."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12887-021-03035-x","article-title":"Preparing newborn screening for the future: a collaborative stakeholder engagement exploring challenges and opportunities to modernizing the newborn screening system","volume":"22","author":"Andrews","year":"2022","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2021.08.075","article-title":"Medication use in the neonatal intensive care unit and changes from 2010 to 2018","volume":"240","author":"Stark","year":"2022","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.earlhumdev.2024.106136_bb0060","first-page":"848","article-title":"Neonatal drug formularies \u2013 a global scope","volume":"10","author":"Shaniv","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0065","doi-asserted-by":"crossref","unstructured":"D. Shaniv, A. Smits, K. Allegaert, On behalf of the Neonatal Drug Formularies Group, A callout for international collaboration, Reply to Giger, E.V., Tilen, R. Comment on \u201cShaniv et al. Neonatal drug formularies-a global scope. Children 2023, 10, 848\u201d, Children (Basel) 10 (11) (2023) 1803.","DOI":"10.3390\/children10111803"},{"issue":"2","key":"10.1016\/j.earlhumdev.2024.106136_bb0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000528012","article-title":"Working group Neonatal Pharmacology (NeoDose project), Development of best evidence dosing recommendations for term and preterm neonates (NeoDose Project)","volume":"120","author":"de Hoop-Sommen","year":"2023","journal-title":"Neonatology"},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41390-023-02779-9","article-title":"Grading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples","volume":"95","author":"Mahoney","year":"2024","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.earlhumdev.2024.106136_bb0080","first-page":"246","article-title":"Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or fever","volume":"16","author":"Zuppa","year":"2011","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.earlhumdev.2024.106136_bb0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2012.148050","article-title":"Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial","volume":"309","author":"Ceelie","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13054-024-04905-3","article-title":"Intermittent intravenous paracetamol versus continuous morphine in infants undergoing cardiothoracic surgery: a multi-center randomized controlled trial","volume":"28","author":"Zeilmaker-Roest","year":"2024","journal-title":"Crit. Care"},{"issue":"11","key":"10.1016\/j.earlhumdev.2024.106136_bb0095","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.earlhumdev.2011.08.014","article-title":"Neonatal drug development","volume":"87","author":"Turner","year":"2011","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0100","unstructured":"Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536\/2014 on clinical trials on medical products for human use, Risk proportionate approaches in clinical trials, https:\/\/health.ec.europa.eu\/system\/files\/2017-08\/2017_04_25_risk_proportionate_approaches_in_ct_0.pdf, 2017."},{"issue":"Suppl. 1","key":"10.1016\/j.earlhumdev.2024.106136_bb0105","first-page":"S141","article-title":"Considerations for drug dosing in premature infants","volume":"61","author":"van den Anker","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.earlhumdev.2024.106136_bb0110","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1681\/ASN.2021101326","article-title":"Maturation of GFR in term-born neonates: an individual participant data meta-analysis","volume":"33","author":"Smeets","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.earlhumdev.2024.106136_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1208\/s12248-022-00688-z","article-title":"Prediction of glomerular filtration rate maturation across preterm and term neonates and young infants using inulin as marker","volume":"24","author":"Wu","year":"2022","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.earlhumdev.2024.106136_bb0120","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/bcp.15978","article-title":"A physiological approach to renal clearance: from premature neonates to adults","volume":"90","author":"Holford","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000079618","article-title":"Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life","volume":"86","author":"Allegaert","year":"2004","journal-title":"Biol. Neonate"},{"issue":"8","key":"10.1016\/j.earlhumdev.2024.106136_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/AAC.00853-19","article-title":"Larger dose reductions of vancomycin required in neonates with patent ductus arteriosus receiving indomethacin versus ibuprofen","volume":"63","author":"Cristea","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-023-00851-0","article-title":"A population model of time-dependent changes in serum creatinine in (near)term neonates with hypoxic-ischemic encephalopathy during and after therapeutic hypothermia","volume":"26","author":"Krzyzanski","year":"2023","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41390-022-02453-6","article-title":"Variations in care of neonates during therapeutic hypothermia: call for care practice bundle implementation","volume":"94","author":"Mohammad","year":"2023","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41372-018-0257-x","article-title":"Successful implementation of an intracranial hemorrhage (ICH) bundle in reducing severe ICH: a quality improvement project","volume":"39","author":"Chiriboga","year":"2019","journal-title":"J. Perinatol."},{"issue":"6","key":"10.1016\/j.earlhumdev.2024.106136_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14140","article-title":"Rates of bronchopulmonary dysplasia following implementation of a novel prevention bundle","volume":"4","author":"Villosis","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"S 01","key":"10.1016\/j.earlhumdev.2024.106136_bb0155","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1055\/a-1817-5522","article-title":"Improving outcomes through a neonatal abstinence syndrome collaborative in Maryland","volume":"41","author":"DiPietro","year":"2024","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0160","doi-asserted-by":"crossref","DOI":"10.1159\/000540002","article-title":"BDP: latest strategies of prevention and treatment","author":"Durlak","year":"2024","journal-title":"Neonatology"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0165","unstructured":"European Medicines Agency, Investigation of medicinal products in the term and preterm neonates \u2013 scientific guideline. Available from: https:\/\/www.ema.europa.eu\/en\/investigation-medicinal-products-term-preterm-neonate-scientific-guideline, 2010."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0170","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for drug evaluation and research (CDER), Center for biologics evaluation and research (CBER), General clinical pharmacology considerations for neonatal studies for drugs and biological product, guidance for industry. Available from: https:\/\/www.fda.gov\/media\/129532\/download, 2022."},{"issue":"5","key":"10.1016\/j.earlhumdev.2024.106136_bb0175","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/pr.2016.221","article-title":"Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates","volume":"81","author":"Ward","year":"2017","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40748-024-00180-w","article-title":"Neonatal blood pressure by birth weight, gestational age, and postnatal age: a systematic review","volume":"10","author":"Dore","year":"2024","journal-title":"Matern. Health Neonatol. Perinatol."},{"issue":"2","key":"10.1016\/j.earlhumdev.2024.106136_bb0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000323699","article-title":"Blood loss related to participation in pharmacokinetic study in preterm neonates","volume":"100","author":"Heidmets","year":"2011","journal-title":"Neonatology"},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41390-024-03094-7","article-title":"Publication recommendations to report laboratory data of neonates \u2013 a modified Delphi approach","volume":"96","author":"Vander Elst","year":"2024","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0091270011433327","article-title":"An algorithm to detect adverse drug reactions in the neonatal intensive care unit","volume":"53","author":"Du","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.earlhumdev.2024.106136_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028096","article-title":"Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool","volume":"6","author":"Gallagher","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.earlhumdev.2024.106136_bb0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/archdischild-2019-317399","article-title":"Development of a neonatal adverse event severity scale through a Delphi consensus approach","volume":"104","author":"Salaets","year":"2019","journal-title":"Arch. Dis. Child."},{"issue":"5","key":"10.1016\/j.earlhumdev.2024.106136_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41390-019-0526-1","article-title":"Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants","volume":"86","author":"Marlow","year":"2019","journal-title":"Pediatr. Res."},{"issue":"21","key":"10.1016\/j.earlhumdev.2024.106136_bb0215","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.2016.3676","article-title":"The potential for postrandomization confounding in randomized clinical trials","volume":"315","author":"Manson","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.earlhumdev.2024.106136_bb0220","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/archdischild-2021-322711","article-title":"Parental perspective on important health outcomes of extremely preterm infants","volume":"107","author":"Jaworski","year":"2022","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/archdischild-2019-316823","article-title":"Inconsistent outcome reporting in large neonatal trials: a systematic review","volume":"105","author":"Webbe","year":"2020","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0230","unstructured":"European Medicines Agency, ACT EU multi-stakeholder workshop: a patient-centered approach to methodologies, Report of the methodology guidance workshop, https:\/\/accelerating-clinical-trials.europa.eu\/system\/files\/2024-03\/ACT%20EU%20multi-stakeholder%20workshop%20on%20methodology%20guidance%20%E2%80%93%20report.pdf, 2023."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0235","unstructured":"Margolis Center for Health Policy, Duke, Measuring clinical benefit in neonatal randomized clinical trials: challenges and opportunities, https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2023-03\/Discussion%20Guide_Neonatal%20RCT%20Workshop.pdf, 2023."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0240","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/archdischild-2023-325445","article-title":"Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in extremely preterm infants: a clinical practice guideline incorporating family values and preferences","volume":"109","author":"Mitra","year":"2024","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"4","key":"10.1016\/j.earlhumdev.2024.106136_bb0245","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/archdischild-2019-317501","article-title":"Core outcomes in neonatology: development of a core outcome set for neonatal research","volume":"105","author":"Webbe","year":"2020","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0250","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060751","article-title":"Heterogeneity and gaps in reporting primary outcomes from neonatal trials","volume":"152","author":"Baba","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0255","series-title":"Essentials of Translational Pediatric Drug Development. From Past Needs to Future Opportunities","first-page":"61","article-title":"The needs form the regulatory authorities\u2019 perspective: current status and worldwide initiatives","author":"Klein","year":"2024"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0260","series-title":"Essentials of Translational Pediatric Drug Development. From Past Needs to Future Opportunities","first-page":"385","article-title":"Regulatory considerations in the design and conduct of pediatric clinical trials","author":"Bhatnagar","year":"2024"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0265","series-title":"Essentials of Translational Pediatric Drug Development. From Past Needs to Future Opportunities","first-page":"451","article-title":"Performing clinical drug trials in acute and critically ill neonates and children","author":"de Cock","year":"2024"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0275","unstructured":"European Medicines Agency, Data analysis and real world interrogation network (DARWIN EU). Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/big-data\/real-world-evidence\/data-analysis-real-world-interrogation-network-darwin-eu, 2024."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3355","article-title":"Real-world evidence to support EU regulatory decision making-results from a pilot of regulatory use cases","author":"Prilla","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0285","unstructured":"Critical Path Institute, C-path and NICHD to share real-world data to advance neonatal drug development. Available from: https:\/\/c-path.org\/c-path-and-nichd-to-share-real-world-data-to-advance-neonatal-drug-development, 2021."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0290","unstructured":"Critical Path Institute, FDA awards C-path grant to use real-world data to generate real-world evidence in neonates. Available from: https:\/\/c-path.org\/fda-awards-c-path-grant-to-use-real-world-data-to-generate-real-world-evidence-in-neonates, 2020."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0295","author":"Modi"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0300","unstructured":"ICH, Committee for medicinal products for human use, ICH guideline E11A on pediatric extrapolation, step 2b. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-e11a-pediatric-extrapolation-step-2b_en.pdf (2022)."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1288376","article-title":"Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: proof-of-concept","volume":"11","author":"de Hoop-Sommen","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0310","unstructured":"European Medicines Agency, Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation \u2013 scientific guideline. Available from: https:\/\/www.ema.europa.eu\/en\/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation-scientific-guideline, 2019."},{"issue":"38","key":"10.1016\/j.earlhumdev.2024.106136_bb0315","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2174\/1381612823666171009143840","article-title":"PBPK in preterm and term neonates: a review","volume":"23","author":"Michelet","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/17425255.2019.1558205","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute","volume":"15","author":"Smits","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.earlhumdev.2024.106136_bb0325","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/psp4.12678","article-title":"A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development, CPT","volume":"10","author":"Johnson","year":"2021","journal-title":"Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0330","article-title":"Physiologically based pharmacokinetic modeling of vancomycin in critically ill neonates: assessing the impact of pathophysiological changes","author":"Weiwei","year":"2024","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.earlhumdev.2024.106136_bb0335","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/pharmaceutics14091957","article-title":"The impact of low cardiac output on propofol pharmacokinetics across age groups \u2013 an investigation using physiologically based pharmacokinetic modelling","volume":"14","author":"Allegaert","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.earlhumdev.2024.106136_bb0340","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/bdd.2301","article-title":"Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates-the impact of metabolising enzyme ontogeny and reduced cardiac output","volume":"42","author":"Olafuyi","year":"2021","journal-title":"Biopharm. Drug Dispos."},{"issue":"1, Suppl","key":"10.1016\/j.earlhumdev.2024.106136_bb0345","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.dmpk.2020.04.326","article-title":"S10.2 Pediatric PBPK: dealing with uncertain parameters and deciding on success criteria for predictability","volume":"35","author":"Johnson","year":"2020","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0350","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bcp.12467","article-title":"Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct","volume":"79","author":"Turner","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0355","unstructured":"European Medicines Agency, Guideline for good clinical practice E6(R2), https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf, 2016."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0360","unstructured":"International Council for Harmonisation of technical requirements for pharmaceuticals for human use, ICH harmonized guideline, Good Clinical Practice (GCP) E6(R3), https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_DraftGuideline_2023_0519.pdf, 2023."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0365","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Adaptive designs for clinical trials of drugs and biologics, guidance for industry, https:\/\/www.fda.gov\/media\/78495\/download, 2019."},{"issue":"6","key":"10.1016\/j.earlhumdev.2024.106136_bb0370","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s43441-022-00448-3","article-title":"The role of master protocols in pediatric drug development","volume":"56","author":"Nelson","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0375","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Masterprotocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.earlhumdev.2024.106136_bb0380","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41390-018-0242-2","article-title":"Recommendations for the design of therapeutic trials for neonatal seizures","volume":"85","author":"Soul","year":"2019","journal-title":"Pediatr. Res."},{"issue":"12","key":"10.1016\/j.earlhumdev.2024.106136_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032592","article-title":"Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view","volume":"9","author":"Folgori","year":"2019","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.earlhumdev.2024.106136_bb0390","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/archdischild-2020-321433","article-title":"Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) working group on preparedness of clinical trials about paediatric medicines process","volume":"106","author":"Siapkara","year":"2021","journal-title":"Arch. Dis. Child."},{"issue":"3","key":"10.1016\/j.earlhumdev.2024.106136_bb0395","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1542\/peds.2011-3455","article-title":"The python\u2019s embrace: clinical research regulation by institutional review boards","volume":"129","author":"Whitney","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0400","unstructured":"Recommendations of the expert groups on clinical trials for the implementation of Regulation (EU) No 536\/2014 on clinical trials for human use. Ethical considerations for clinical trials on medicinal products conducted with minors, revision 1, https:\/\/health.ec.europa.eu\/system\/files\/2018-02\/2017_09_18_ethical_consid_ct_with_minors_0.pdf, 2017."},{"issue":"6","key":"10.1016\/j.earlhumdev.2024.106136_bb0405","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-0038-1637766","article-title":"Capacities and competences for drug evaluation in European neonatal intensive care units: a survey and key issues for improvement","volume":"35","author":"Elie","year":"2018","journal-title":"Am. J. Perinatol."},{"issue":"5","key":"10.1016\/j.earlhumdev.2024.106136_bb0410","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/apa.17165","article-title":"Practical approaches for supporting informed consent in neonatal clinical trials","volume":"113","author":"Wootton","year":"2024","journal-title":"Acta Paediatr."},{"issue":"6","key":"10.1016\/j.earlhumdev.2024.106136_bb0415","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40272-021-00473-z","article-title":"Deferred consent in neonatal clinical research: why, when, how?","volume":"23","author":"Imbulana","year":"2021","journal-title":"Paediatr. Drugs"},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0420","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/archdischild-2023-325900","article-title":"Parental perspectives about information and deferred versus two-stage consent in studies of neonatal asphyxia","volume":"109","author":"Maiwald","year":"2023","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"1","key":"10.1016\/j.earlhumdev.2024.106136_bb0425","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/archdischild-2021-322960","article-title":"Implementing two-stage consent pathway in neonatal trials","volume":"108","author":"Mitchell","year":"2023","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"12","key":"10.1016\/j.earlhumdev.2024.106136_bb0430","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1038\/s41372-021-01220-5","article-title":"The culture of research communication in neonatal intensive care units: key stakeholder perspectives","volume":"41","author":"Degl","year":"2021","journal-title":"J. Perinatol."},{"issue":"4","key":"10.1016\/j.earlhumdev.2024.106136_bb0435","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/ANC.0000000000001059","article-title":"International Neonatal Consortium (INC) Communications Workgroup, Nurses\u2019 knowledge, communication needs, and future directions in neonatal research: results of an international survey","volume":"23","author":"Sundquist Beauman","year":"2023","journal-title":"Adv. Neonatal Care"},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0440","unstructured":"Institute for advanced clinical trials for children (iACT), https:\/\/iactc.org, 2014."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0445","unstructured":"MIYRN, better health for mothers and children, https:\/\/www.micyrn.ca, 2024."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0450","unstructured":"Conect4children, https:\/\/conect4children.eu, 2024."},{"key":"10.1016\/j.earlhumdev.2024.106136_bb0455","unstructured":"Ecrin, https:\/\/ecrin.org, 2024."},{"issue":"4","key":"10.1016\/j.earlhumdev.2024.106136_bb0460","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bcp.15669","article-title":"Implementation of centralized pharmacovigilance system in academic pan-European clinical trials: experience from EU-response and conect4children consortia","volume":"89","author":"Terzic","year":"2023","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Early Human Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378378224002056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378378224002056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T23:12:24Z","timestamp":1733526744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378378224002056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":92,"alternative-id":["S0378378224002056"],"URL":"https:\/\/doi.org\/10.1016\/j.earlhumdev.2024.106136","relation":{},"ISSN":["0378-3782"],"issn-type":[{"value":"0378-3782","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advocating for drug development in newborn infants","name":"articletitle","label":"Article Title"},{"value":"Early Human Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.earlhumdev.2024.106136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106136"}}